FP 008 - Fapon Biopharma
Alternative Names: FP-008 - Fapon BiopharmaLatest Information Update: 13 Aug 2025
At a glance
- Originator Fapon Biopharma
- Class Antibodies; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 10 replacements; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 06 Aug 2025 NMPA approves IND application for FP 008 in Solid tumours
- 12 Jun 2025 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT06990698)
- 30 May 2025 Fapon Biopharma plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) (IV, Injection), in August 2025 (NCT06990698)